Long-term treatment of rheumatoid arthritis with adalimumab

References

• FilipovicIWalkerDForsterFCurryASQuantifying the economic burden of productivity loss in rheumatoid arthritisRheumatology (Oxford)20115061083109021245074
   PubMed Web of Science ®Google Scholar
• ScottDLWolfeFHuizingaTWRheumatoid arthritisLancet201037697461094110820870100
   PubMed Web of Science ®Google Scholar
• TakeuchiTRevolutionary change in rheumatoid arthritis management with biological therapyKeio J Med2011603758121979826
   PubMedGoogle Scholar
• PeschonJJTorranceDSStockingKLTNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammationJ Immunol199816029439529551933
   PubMed Web of Science ®Google Scholar
• MurdacaGColomboBMCagnatiPGulliRSpanòFPuppoFUpdate upon efficacy and safety of TNF-α inhibitorsExpert Opin Drug Saf20121111522010813
   PubMed Web of Science ®Google Scholar
• MurdacaGColomboBMPuppoFEmerging biological drugs: a new therapeutic approach for systemic lupus erythematosus. An update upon efficacy and adverse eventsAutoimmun Rev2011111566021835271
   PubMed Web of Science ®Google Scholar
• MurdacaGColomboBMPuppoFAdalimumab for the treatment of immune-mediated diseases: an update on old and recent indicationsDrugs Today (Barc)201147427728821573251
   PubMed Web of Science ®Google Scholar
• MurdacaGColomboBMPuppoFAnti-TNF-alpha inhibitors: a new therapeutic approach for inflammatory immune-mediated diseases: an update upon efficacy and adverse eventsInt J Immunopathol Pharmacol200922355756519822072
   PubMed Web of Science ®Google Scholar
• MurdacaGColomboBMBarabinoGCaitiMCagnatiPPuppoFAnti-tumor necrosis factor-α treatment with infliximab for disseminated granuloma annulareAm J Clin Dermatol201011643743920515080
   PubMed Web of Science ®Google Scholar
• PuppoFMurdacaGGhioMIndiveriFEmerging biologic drugs for the treatment of rheumatoid arthritisAutoimmun Rev20054853754116214092
   PubMed Web of Science ®Google Scholar
• MurdacaGSpanòFPuppoFSelective TNF-α inhibitor-induced injection site reactionsExpert Opin Drug Saf201312218719323330811
   PubMed Web of Science ®Google Scholar
• MurdacaGSpanòFMiglinoMPuppoFEffects of TNF-α inhibitors upon the mechanisms of action of VEGFImmunotherapy20135211311523413901
   PubMed Web of Science ®Google Scholar
• BreedveldFCWeismanMHKavanaughAFThe PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatmentArthritis Rheum2006541263716385520
   PubMed Web of Science ®Google Scholar
• van der HeijdeDBreedveldFCKavanaughADisease activity, physical function, and radiographic progression after long-term therapy with adalimumab plus methotrexate: 5-year results of PREMIERJ Rheumatol201037112237224620889601
   PubMed Web of Science ®Google Scholar
• WeinblattMEKeystoneECFurstDEAdalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trialArthritis Rheum2003481354512528101
   PubMed Web of Science ®Google Scholar
• van de PutteLBAtkinsCMalaiseMEfficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failedAnn Rheum Dis200463550851615082480
   PubMed Web of Science ®Google Scholar
• KeystoneECKavanaughAFSharpJTRadiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trialArthritis Rheum20045051400141115146409
   PubMed Web of Science ®Google Scholar
• FurstDESchiffMHFleischmannRMAdalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis)J Rheumatol200330122563257114719195
   PubMed Web of Science ®Google Scholar
• KavanaughAFleischmannRMEmeryPClinical, functional, and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomized, controlled OPTIMA studyAnn Rheum Dis2013721647122562973
   PubMed Web of Science ®Google Scholar
• ChangJGirgisLClinical use of anti-TNF-alpha biological agents – a guide for GPsAust Fam Physician200736121035103818075630
   PubMed Web of Science ®Google Scholar
• InoueEYamanakaHHaraMTomatsuTKamataniNComparison of Disease Activity Score (DAS)28-erythrocyte sedimentation rate and DAS28-C-reactive protein threshold valuesAnn Rheum Dis200766340740916926186
   PubMed Web of Science ®Google Scholar
• RoachDRBeanAGDemangelCFranceMPBriscoeHBrittonWJTNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infectionJ Immunol200216894620462711971010
   PubMed Web of Science ®Google Scholar
• WinthropKLRisk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factorNat Clin Pract Rheumatol200621160261017075599
   PubMedGoogle Scholar
• Gonnet-GraciaCBarnetcheTRichezCBlancoPDehaisJSchaeverbekeTAntinuclear antibodies, anti-DNA, and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockersClin Exp Rheumatol200826340140718578960
   PubMed Web of Science ®Google Scholar
• PavelkaKKavanaughAFRubbert-RothAFerraccioliGOptimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying antirheumatic drugsRheumatology (Oxford)201251Suppl 5v12v2122718922
   PubMed Web of Science ®Google Scholar
• KrieckaertCLNurmohamedMTWolbinkGLemsWFChanges in bone mineral density during long-term treatment with adalimumab in patients with rheumatoid arthritis: a cohort studyRheumatology (Oxford)201352354755323221326
   PubMed Web of Science ®Google Scholar
• EngvallILTengstrandBBrismarKHafströmIInfliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomized study over 21 monthsArthritis Res Ther2010125R19720964833
   PubMed Web of Science ®Google Scholar
• BriotKGossecLKoltaSDougadosMRouxCProspective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving antitumor necrosis factor-alpha treatmentJ Rheumatol200835585586118381782
   PubMed Web of Science ®Google Scholar
• BakerJFGeorgeMBakerDGToedterGVon FeldtJMLeonardMBAssociations between body mass, radiographic joint damage, adipokines and risk factors for bone loss in rheumatoid arthritisRheumatology (Oxford)201150112100210721890621
   PubMed Web of Science ®Google Scholar
• TakeuchiTYamanakaHIshiguroNAdalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 studyAnn Rheum Dis Epub1112013
   Web of Science ®Google Scholar
• WittamerVGrégoireFRobberechtPVassartGCommuniDParmentierMThe C-terminal nonapeptide of mature chemerin activates the chemerin receptor with low nanomolar potencyJ Biol Chem2004279119956996214701797
   PubMed Web of Science ®Google Scholar
• HereniusMMOliveiraASWijbrandtsCAGerlagDMTakPPLebreMCAnti-TNF therapy reduces serum levels of chemerin in rheumatoid arthritis: a new mechanism by which anti-TNF might reduce inflammationPLoS One201382e5780223460910
   PubMed Web of Science ®Google Scholar
• TakemuraSBraunACrowsonCLymphoid neogenesis in rheumatoid synovitisJ Immunol200116721072108011441118
   PubMed Web of Science ®Google Scholar
• MurdacaGColomboBMPuppoFThe role of Th17 lymphocytes in the autoimmune and chronic inflammatory diseasesIntern Emerg Med20116648749521258875
   PubMed Web of Science ®Google Scholar
• ChiangEYKolumamGAYuXTargeted depletion of lymphotoxin-alpha-expressing TH1 and TH17 cells inhibits autoimmune diseaseNat Med200915776677319561618
   PubMed Web of Science ®Google Scholar
• MurdacaGColomboBMContiniPPuppoFDetermination of lymphotoxin-alpha levels in patients with psoriatic arthritis undergoing etanercept treatmentJ Interferon Cytokine Res201232627727922480318
   PubMed Web of Science ®Google Scholar
• MurdacaGColomboBMCagnatiPGulliRSpanòFPuppoFEndothelial dysfunction in rheumatic autoimmune diseasesAtherosclerosis2012224230931722673743
   PubMed Web of Science ®Google Scholar
• PudduPPudduGMCraveroEDe PascalisSMuscariAThe emerging role of cardiovascular risk factor-induced mitochondrial dysfunction in atherogenesisJ Biomed Sci20091611220003216
   PubMed Web of Science ®Google Scholar
• ButtariBProfumoEMatteiVOxidized beta2-glycoprotein I induces human dendritic cell maturation and promotes a T helper type 1 responseBlood2005106123880388716099886
   PubMed Web of Science ®Google Scholar
• ArvieuxJRegnaultVHachullaEDarnigeLBerthouFYouinouPOxidation of beta2-glycoprotein I (beta2GPI) by the hydroxil radical alters phospholipid binding and modulates recognition by anti-beta2GPI autoantibodiesThromb Haemost20018641070107611686326
   PubMed Web of Science ®Google Scholar
• MurdacaGSpanòFCagnatiPPuppoFFree radicals and endothelial dysfunction: potential positive effects of TNF-α inhibitorsRedox reportin press
   Web of Science ®Google Scholar
• CiprandiGMurdacaGColomboBMDe AmiciMMarsegliaGLSerum vascular endothelial growth factor in allergic rhinitis and systemic lupus erythematosusHum Immunol200869851051218577409
   PubMed Web of Science ®Google Scholar
• CiprandiGColomboBMMurdacaGDe AmiciMSerum vascular endothelial growth factor and sublingual immunotherapyAllergy200863794594618588566
   PubMed Web of Science ®Google Scholar
• KerekesGSzekaneczZDérHEndothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunityJ Rheumatol200835339840618203326
   PubMed Web of Science ®Google Scholar
• ColomboBMCacciapagliaFPuntoniMTraditional and nontraditional risk factors in accelerated atherosclerosis in systemic lupus erythematosus: role of vascular endothelial growth factor (VEGATS Study)Autoimmun Rev20098430931518976721
   PubMed Web of Science ®Google Scholar
• ColomboBMMurdacaGCaitiMIntima-media thickness: a marker of accelerated atherosclerosis in women with systemic lupus erythematosusAnn N Y Acad Sci2007110812112617893978
   PubMed Web of Science ®Google Scholar
• DulaiRPerryMTwycross-LewisRMorrisseyDAtzeniFGreenwaldSThe effect of tumor necrosis factor-α antagonists on arterial stiffness in rheumatoid arthritis: a literature reviewSemin Arthritis Rheum20124211822475245
   PubMed Web of Science ®Google Scholar
• SzekaneczZKerekesGSoltészPVascular effects of biologic agents in RA and spondyloarthropathiesNat Rev Rheumatol200951267768419901918
   PubMed Web of Science ®Google Scholar
• Gonzalez-JuanateyCVazquez-RodriguezTRMiranda-FilloyJAAnti-TNF-alpha-adalimumab therapy is associated with persistent improvement of endothelial function without progression of carotid intima-media wall thickness in patients with rheumatoid arthritis refractory to conventional therapyMediators Inflamm2012201267426522899879
   PubMed Web of Science ®Google Scholar
• BenderNKHeiligCEDröllBWohlgemuthJArmbrusterFPHeiligBImmunogenicity, efficacy, and adverse events of adalimumab in RA patientsRheumatol Int200727326927417006705
   PubMed Web of Science ®Google Scholar